- Home
- WCT vs UBX Comparison
WCT vs UBX Comparison
Compare WCT & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- UBX
- Stock Information
- Founded
- WCT 2012
- UBX 2009
- Country
- WCT Hong Kong
- UBX United States
- Employees
- WCT N/A
- UBX N/A
- Industry
- WCT
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- UBX Health Care
- Exchange
- WCT NYSE
- UBX Nasdaq
- Market Cap
- WCT 13.9M
- UBX 12.7M
- IPO Year
- WCT 2024
- UBX 2018
- Fundamental
- Price
- WCT $0.27
- UBX $0.68
- Analyst Decision
- WCT
- UBX Strong Buy
- Analyst Count
- WCT 0
- UBX 3
- Target Price
- WCT N/A
- UBX $4.67
- AVG Volume (30 Days)
- WCT 1.1M
- UBX 168.7K
- Earning Date
- WCT 05-16-2025
- UBX 04-22-2025
- Dividend Yield
- WCT N/A
- UBX N/A
- EPS Growth
- WCT N/A
- UBX N/A
- EPS
- WCT N/A
- UBX N/A
- Revenue
- WCT $2,309,218.00
- UBX N/A
- Revenue This Year
- WCT N/A
- UBX N/A
- Revenue Next Year
- WCT N/A
- UBX N/A
- P/E Ratio
- WCT N/A
- UBX N/A
- Revenue Growth
- WCT N/A
- UBX N/A
- 52 Week Low
- WCT $0.12
- UBX $0.66
- 52 Week High
- WCT $9.36
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- UBX 32.99
- Support Level
- WCT N/A
- UBX $0.66
- Resistance Level
- WCT N/A
- UBX $0.73
- Average True Range (ATR)
- WCT 0.00
- UBX 0.05
- MACD
- WCT 0.00
- UBX 0.01
- Stochastic Oscillator
- WCT 0.00
- UBX 11.05
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.